MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.
Stock data | 2024 | Change |
---|---|---|
Price | $46.79 | N/A |
Market Cap | $2.80B | N/A |
Shares Outstanding | 59.94M | N/A |
Employees | 20.00 | N/A |